Cargando…

Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy

BACKGROUND/AIMS: Safety for tumor necrosis factor inhibitors (TNFi) in cancer has been focused on risk of incident malignancies, but studies on prognostic effects have been scarce. We determined survival and recurrence rates at 1, 2, and 5 years after cancer diagnosis in patients with and without co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phan, Hiep, Weideman, Rick A., Cipher, Daisha J., Feagins, Linda A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385568/ https://www.ncbi.nlm.nih.gov/pubmed/32252501 http://dx.doi.org/10.5217/ir.2019.09140

Ejemplares similares

REMINISCENCE AND DIGITAL STORYTELLING TO IMPROVE WELL-BEING OF OLDER ADULTS WITH COGNITIVE IMPAIRMENT
por: Xu, Ling, et al.
Publicado: (2022)

Tumor necrosis factor-α inhibitor use in patients with malignancy: is it safe?
por: Oh, Gyu Man, et al.
Publicado: (2020)

Relationships among stress, resilience, and incivility in undergraduate nursing students and faculty during the COVID-19 pandemic: Policy implications for nurse leaders
por: Urban, Regina W., et al.
Publicado: (2021)

Reminiscence and Digital Storytelling to Improve the Social and Emotional Well-Being of Older Adults With Alzheimer’s Disease and Related Dementias: Protocol for a Mixed Methods Study Design and a Randomized Controlled Trial
por: Xu, Ling, et al.
Publicado: (2023)

ATTITUDES TOWARD AGING AMONG COLLEGE STUDENTS: RESULTS FROM THE INTERGENERATIONAL CONNECTIONS PROJECT
por: Xu, Ling, et al.
Publicado: (2022)

The Senior Companion Program Plus for African American Caregivers of Persons With Alzheimer Disease and Related Dementias: Protocol for a Randomized Controlled Trial
por: Fields, Noelle L, et al.
Publicado: (2023)

Concomitant disseminated histoplasmosis and disseminated tuberculosis after tumor necrosis factor inhibitor treatment: a case report
por: Muñoz-Oca, Juan E., et al.
Publicado: (2017)

Attitudes toward Aging among College Students: Results from an Intergenerational Reminiscence Project
por: Xu, Ling, et al.
Publicado: (2023)

Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research
por: Kim, Hye Won, et al.
Publicado: (2016)

Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate
por: O’Dell, James R, et al.
Publicado: (2018)

The Senior Companion Program Plus: An Innovative Training Approach for Alzheimer’s Disease and Related Dementia
por: Fields, Noelle L., et al.
Publicado: (2023)

Tumor necrosis factor inhibitors – state of knowledge
por: Lis, Krzysztof, et al.
Publicado: (2014)

The Senior Companion Program Plus (SCP Plus): Examining the Preliminary Effectiveness of a Lay Provider Program to Support African American Alzheimer’s Disease and Related Dementias (ADRD) Caregivers
por: Xu, Ling, et al.
Publicado: (2023)

Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis
por: Ma, Zeren, et al.
Publicado: (2017)

Methotrexate-related adverse events and impact of concomitant treatment with folic acid and tumor necrosis factor-alpha inhibitors: An assessment using the FDA adverse event reporting system
por: Onda, Kenji, et al.
Publicado: (2023)

A human inhibitor of tumor necrosis factor alpha
Publicado: (1988)

Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis
por: Callejas-Rubio, José Luis, et al.
Publicado: (2008)

Tumor Necrosis Factor Alpha-Induced Proteins in Malignant Tumors: Progress and Prospects
por: Guo, Fang, et al.
Publicado: (2020)

MODL-01. SAFETY IN CONCOMITANT USE OF MEK AND BRAF INHIBITORS WITH BEVACIZUMAB
por: Winzent, Shelby, et al.
Publicado: (2020)

Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis
por: Yang, Nicole, et al.
Publicado: (2019)

Efficacy and safety of recombinant human tumor necrosis factor application for the treatment of malignant pleural effusion caused by lung cancer
por: Li, Qian, et al.
Publicado: (2015)

Mechanisms of coagulative necrosis in malignant epithelial tumors (Review)
por: CARUSO, ROSARIO A., et al.
Publicado: (2014)

The adverse drug reactions to tumor necrosis factor alpha inhibitor
por: Park, Hye-Kyung, et al.
Publicado: (2014)

Tumor Necrosis Factor Alpha Inhibitor-Induced Acute Pancreatitis
por: Werlang, Monia E., et al.
Publicado: (2017)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
por: Sharon, Yael, et al.
Publicado: (2020)

Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far
por: Jani, Meghna, et al.
Publicado: (2018)

Rheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
por: Solehan, Hana Maizuliana bt, et al.
Publicado: (2011)

Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis
por: Micheroli, Raphael, et al.
Publicado: (2017)

Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
por: Kucharz, Eugeniusz Józef, et al.
Publicado: (2021)

Tumor necrosis factor‐α inhibitor‐induced follicular psoriasiform eruption
por: Goldberger, Tal, et al.
Publicado: (2022)

TNFPred: identifying tumor necrosis factors using hybrid features based on word embeddings
por: Nguyen, Trinh-Trung-Duong, et al.
Publicado: (2020)

Acquired Factor VIII Inhibitor in a Patient of Rheumatoid Arthritis on Tumor Necrosis Factor Inhibitor Therapy
por: Mori, Tomoyo, et al.
Publicado: (2018)

Determinants of Tumor Necrosis Factor Inhibitor Use in Juvenile Spondyloarthropathy and Impact on Clinical Disease Outcomes
por: Oliver, Melissa, et al.
Publicado: (2021)

Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence
por: Yu, Jongwook, et al.
Publicado: (2022)

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study
por: Kim, Seoyoung C., et al.
Publicado: (2017)

Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor
Publicado: (1986)

Real-Life Safety and Effectiveness of Dupilumab in Patients with Concomitant Malignancies: a Case Series
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Success and safety of endoscopic treatments for concomitant biliary and duodenal malignant stenosis: A review of the literature
por: Mangiavillano, Benedetto, et al.
Publicado: (2019)

Predictors of Treatment Initiation with Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis
por: Desai, Rishi J., et al.
Publicado: (2014)

Predictive factors for effective selection of Interleukin-6 inhibitor and tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis
por: Hayashi, Shinya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hlanl4rtk3sidfv6vqc7krnu8d